DNA strands interwoven in a blooming flower, symbolizing hope in ovarian cancer treatment.

Olaparib's Promise: Extending Lives in Advanced Ovarian Cancer

Elliot Brynn monogram
Elliot Brynn in Health & Wellness November 2026 • 5 min read.

"Discover how olaparib maintenance therapy significantly boosts progression-free survival in women with BRCA1/2-mutated ovarian cancer, offering new hope and transforming treatment outcomes."


Ovarian cancer remains one of the most challenging gynecological malignancies to treat. Despite advancements in surgical techniques and chemotherapy regimens, many women experience recurrence, highlighting the urgent need for more effective treatment strategies. Now, a promising development has emerged from a recent study, shedding light on a new maintenance therapy that significantly improves outcomes for women with advanced ovarian cancer.

The new study focuses on olaparib, a PARP (poly ADP-ribose polymerase) inhibitor, and its impact on progression-free survival in patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer. BRCA1 and BRCA2 are genes involved in DNA repair; mutations in these genes are known to increase the risk of ovarian and breast cancers. When these genes are mutated, cancer cells become more susceptible to PARP inhibitors, which can disrupt DNA repair mechanisms and lead to cell death.

The phase 3 clinical trial led by Kathleen Moore at the Stephenson Cancer Center at the University of Oklahoma, alongside a team of dedicated colleagues, marks a significant step forward in ovarian cancer treatment. By evaluating the effectiveness of olaparib as a maintenance therapy, this study offers renewed hope for extending the lives of women battling this challenging disease. With a focus on improving progression-free survival, olaparib is emerging as a vital tool in the fight against advanced ovarian cancer, paving the way for more personalized and effective treatment strategies.

AI Search Multiple angles on this topic

Ovarian Cancer and Olaparib's Role

Ovarian cancer is women’s eighth most common cancer and has the highest mortality rates among malignancies of the female reproductive system. PARP inhibitors have reshaped treatment for metastatic ovarian cancer, particularly as maintenance therapy after platinum-based chemotherapy. Olaparib is approved in the United States and European Union for maintenance treatment of women with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer with BRCA1/2 mutations in the first-line setting or platinum-sensitive relapse after a response to platinum-based chemotherapy.

Maintenance Therapy and Remaining Uncertainty

The evaluated standard approach is olaparib maintenance therapy for patients with advanced ovarian cancer who achieved a complete or partial response to platinum-based chemotherapy. An updated meta-analysis examined randomized controlled trials in both first-line and recurrent-disease settings using searches of PubMed, Embase, and the Cochrane Library. Its rationale reflects continuing uncertainty about the magnitude of benefit across molecular subgroups and about safety, despite olaparib’s widespread use.

From First PARP Inhibitor to Major Approvals

Olaparib was the first PARP inhibitor developed for ovarian cancer. The clinical development history highlighted in the review includes Study 42, Study 19, and SOLO2. Approvals based on this development represent a major advance for women with advanced ovarian cancer who are in complete or partial response after initial platinum-based chemotherapy.

Olaparib's Impact on Progression-Free Survival: What the Study Revealed

DNA strands interwoven in a blooming flower, symbolizing hope in ovarian cancer treatment.

The phase 3 trial, a rigorous and carefully designed study, enrolled 391 women diagnosed with stage 3 or 4 ovarian cancer who had demonstrated a positive response to platinum-based chemotherapy and carried mutations in BRCA1, BRCA2, or both. These women were randomly assigned in a 2:1 ratio to receive either 300 mg of olaparib twice daily or a placebo. This randomized, double-blind approach ensured the integrity of the study, minimizing bias and providing reliable results.

The primary endpoint of the study was investigator-assessed progression-free survival, a critical measure that indicates the length of time during and after treatment that a patient lives with the disease without it getting worse. With a median follow-up of 41 months, the results were compelling. In the placebo group, the median progression-free survival from the end of chemotherapy was 13.8 months. In stark contrast, the median progression-free survival was not reached in the olaparib group, signifying a substantial improvement.

  • Significant Improvement: 60% of patients who received olaparib were progression-free at 3 years, compared to only 27% in the placebo group.
  • Hazard Ratio: The hazard ratio was 0.30 (95% CI 0.23-0.41; p<0.001), indicating a 70% reduction in the risk of disease progression or death with olaparib.
  • Toxicity: The toxicity profile of olaparib was consistent with previous studies, suggesting that the treatment is generally well-tolerated.
AI Search Multiple angles on this topic

Seven-Year SOLO1 Survival Results

The SOLO1/GOG 3004 trial reported overall survival and treatment-free outcomes at a 7-year follow-up among patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. At 7 years, 67.0% of patients receiving olaparib were alive, compared with 46.5% receiving placebo. The proportions alive without a first subsequent treatment were 45.3% with olaparib and 20.6% with placebo.

Comparing Approved PARP Inhibitors

Network meta-analysis has been used to compare the efficacy and safety of different PARP inhibitors in ovarian cancer, including olaparib, rucaparib, and niraparib. A 2025 review states that these three PARP inhibitors had been approved by the U.S. Food and Drug Administration for ovarian cancer and were available to patients. It also notes that they have different clinical indications and toxicity profiles and that authoritative guidelines such as ASCO recommended them as maintenance therapy for platinum-sensitive recurrent ovarian cancer.

This landmark study highlights olaparib as a potentially transformative maintenance therapy for women with advanced ovarian cancer and BRCA1/2 mutations. The magnitude of improvement in progression-free survival is particularly encouraging and represents a significant advancement in the treatment of this challenging disease. This study is poised to influence clinical practice, offering new hope and improved outcomes for patients with advanced ovarian cancer.

The Future of Ovarian Cancer Treatment: A Promising Horizon

The success of olaparib in improving progression-free survival is just the beginning. As research continues, there is hope that the integration of PARP inhibitors with other therapies, such as immunotherapy and anti-angiogenesis agents, may further enhance treatment outcomes. These advancements offer a beacon of hope for women with advanced ovarian cancer, potentially leading to increased cure rates and improved quality of life. As Jonathan Ledermann aptly stated, "Progression-free survival is holding up long after the drug has been stopped... a challenge for the future will be ensuring that patients with ovarian cancer are tested for BRCA mutations at diagnosis."

AI Search Multiple angles on this topic

Balancing Benefit and Toxicity

Expert discussion of olaparib in ovarian cancer emphasizes both its therapeutic role and its safety profile. The review examines recent randomized trials of the FDA-approved PARP inhibitors olaparib, rucaparib, and niraparib. Its focus on toxicity and risks underscores that clinical decisions must consider potential harms alongside treatment benefit.

Targeted Therapy and Long-Term Outcomes

Future progress in ovarian cancer is expected to involve improving existing treatments and implementing new promising methods. Targeted therapies are described as particularly promising, with bevacizumab, a VEGF inhibitor, and olaparib, a poly(ADP-ribose) polymerase inhibitor, identified as approved therapies. A 2026 update on PARP inhibitors reports a 43% reduction in disease progression risk while highlighting the need to balance long-term survival with quality of life.

Access, Affordability, and Eligibility

In May 2020, the FDA approved olaparib combined with bevacizumab for first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer after response to first-line platinum-based chemotherapy in patients with homologous recombination deficiency-positive status. Broader reviews identify ovarian cancer as a health and economic burden, particularly in low- and middle-income countries. They propose de-escalation of targeted therapy as one strategy to improve accessibility and affordability while considering patient preferences.

What the survival findings add up to

The longer median survival with olaparib is a favorable signal, but the result does not establish a statistically significant overall-survival benefit. Interpretation is also complicated because some participants assigned placebo later received a PARP inhibitor, and the reported comparison was not adjusted for that treatment.[1]

In the newly diagnosed setting, the reported survival improvement was described as clinically meaningful but not statistically significant under the prespecified criteria. That supports a distinction between a promising long-term outcome and proof of a survival effect by those criteria.[2]

How survival results differ by treatment setting

Within the HRD-positive population in that combination-treatment comparison, olaparib plus bevacizumab was associated with longer overall survival and a higher five-year survival rate than placebo plus bevacizumab. Updated progression-free survival also favored the combination in that subgroup.[3]

NICE guidance recommends olaparib maintenance as an option for BRCA mutation-positive, advanced high-grade epithelial ovarian cancer after response to first-line platinum chemotherapy, placing the treatment in a defined clinical setting rather than establishing that the survival results apply to every ovarian cancer population.[4]

What further evidence would need to clarify

  • Would the overall-survival comparison in relapsed disease remain similar if later PARP inhibitor treatment in the placebo group were accounted for?[1]
  • How much does the survival pattern seen with olaparib plus bevacizumab in the HRD-positive subgroup differ from outcomes in the broader intention-to-treat population?[3]

Sources

  1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-c (pubmed.ncbi.nlm.nih.gov)
  2. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial (pmc.ncbi.nlm.nih.gov)
  3. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. (pubmed.ncbi.nlm.nih.gov)
  4. Recommendations | Ovarian cancer: recognition and initial management | Guidance | NICE (www.nice.org.uk)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is Olaparib and how does it work?

Olaparib is a type of medication called a PARP (poly ADP-ribose polymerase) inhibitor. It works by targeting and disrupting DNA repair mechanisms in cancer cells, particularly those with BRCA1/2 mutations, ultimately leading to cell death. This is significant because BRCA1/2 mutations increase the risk of ovarian cancer. When these mutated cells are exposed to Olaparib their DNA repair process is disrupted, inducing cell death. Olaparib is used as a maintenance therapy to extend the period of time patients live without the cancer progressing after they have responded positively to chemotherapy.

2

What does progression-free survival mean, and why is it so important in studies?

Progression-free survival is a key measure in cancer treatment. It refers to the length of time during and after treatment that a patient lives with the disease without it getting worse. This is important because it indicates how effective a treatment is in controlling the cancer and preventing its progression. A longer progression-free survival suggests the treatment is successfully keeping the cancer at bay, improving the patient's overall prognosis and quality of life. In clinical trials, progression-free survival is often used as a primary endpoint to assess the efficacy of new therapies, like Olaparib, in managing advanced ovarian cancer.

3

What are BRCA1 and BRCA2 mutations, and why are they important when considering Olaparib treatment?

BRCA1 and BRCA2 are genes involved in DNA repair. Mutations in these genes increase the risk of certain cancers, including ovarian and breast cancers. These mutations are significant because they make cancer cells more vulnerable to PARP inhibitors like Olaparib. When BRCA1/2 genes are mutated, cancer cells have difficulty repairing damaged DNA. Olaparib exploits this weakness by further inhibiting the PARP enzyme, which is also involved in DNA repair, causing cancer cells to die. Identifying BRCA1/2 mutations in patients with ovarian cancer is crucial for determining if Olaparib maintenance therapy would be an effective treatment option.

4

What is maintenance therapy and how does Olaparib fit into that strategy for treating ovarian cancer?

Maintenance therapy, in the context of ovarian cancer, refers to treatment given after initial therapies like surgery and chemotherapy to help keep the cancer from returning. It aims to prolong remission and extend progression-free survival. Olaparib is used as a maintenance therapy for women with advanced ovarian cancer who have BRCA1/2 mutations and have responded positively to platinum-based chemotherapy. By continuing treatment with Olaparib after the initial response, the goal is to prevent the cancer from progressing or recurring, offering a longer period of disease control and improved quality of life.

5

Can you explain how the phase 3 clinical trial was conducted and why its design is important?

The phase 3 clinical trial was a carefully designed study to evaluate the effectiveness of Olaparib as a maintenance therapy. It involved 391 women with stage 3 or 4 ovarian cancer who had BRCA1/2 mutations and had responded positively to platinum-based chemotherapy. The women were randomly assigned to receive either Olaparib or a placebo in a double-blind approach. This rigorous study design minimized bias and ensured reliable results, showing a significant improvement in progression-free survival for those treated with Olaparib. The success of this trial provides strong evidence supporting the use of Olaparib as a standard maintenance therapy for women with advanced ovarian cancer and BRCA1/2 mutations.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.